Fingolimod: all 75 studies that test it

Page 1 of 1. Open to participants first (8), then studies with results posted, then the rest; newest registration first within each.

• A Study to Learn About the Safety of Diroximel Fumarate (DRF) and Dimethyl Fumarate (DMF) and Their Effects on Relapses in Pediatric Participants With Relapsing Forms of Multiple Sclerosis (RMS)Not yet recruitingNCT07483632Phase 3
• Study to Assess Effects of Ublituximab in Pediatric Participants With Relapsing Forms of Multiple SclerosisRecruitingNCT07220252Phase 2/3
• Phase 2 Study of Fingolimod in Lung CancersRecruitingNCT06424067Phase 2
• Fingolimod in Minimal Invasive Treatment of Intracerebral HemorrhageNot yet recruitingNCT06087965Phase 1/2
• Fingolimod for Type 2 Diabetes MellitusRecruitingNCT05307731Phase 4
• Fingolimod for the Abrogation of Interstitial Fibrosis and Tubular Atrophy Following Kidney TransplantationEnrolling by invitationNCT05285878Phase 2
• Combinating Fingolimod With Alteplase Bridging With Thrombectomy in Acute Ischemic StrokeRecruitingNCT04675762Phase 2
• Safety and Efficacy Study of Fingolimod in Taiwanese Adults (≥ 20years) With Relapsing Remitting Multiple SclerosisRecruitingNCT04480853Phase 4
• Study of Efficacy and Safety of Fingolimod (Gilenya) 0.5 mg in Chinese Patients With Relapsing Multiple Sclerosis (RMS) PatientsCompletedNCT04667949Phase 4Results posted
• Fingolimod as a Treatment of Cerebral Edema After Intracerebral HemorrhageCompletedNCT04088630Early Phase 1Results posted
• A Study of Immune Phenotype Biomarkers in Patients With Relapsing Multiple Sclerosis (RMS) After Treatment With 0.5mg FingolimodCompletedNCT03257358Phase 4Results posted
• Follow up Study of Patients on Fingolimod Who Were Enrolled in the Original Biobank Study (CFTY720DDE01)CompletedNCT02720107Phase 4Results posted
• Fingolimod Effect on Cytokine and Chemokine LevelsCompletedNCT02373098Phase 4Results posted
• Long-term, Open-label, Multicenter Study Assessing Long-term Cardiovascular RisksCompletedNCT02232061Phase 4Results posted
• Evaluation of the Autonomic Nervous System During First-dosing With 0.5mg of Fingolimod (Gilenya) in Patients With Relapsing-remitting MSCompletedNCT02048072Phase 4Results posted
• Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple SclerosisActive, not recruitingNCT01892722Phase 3Results posted
• Gilenya in Amyotrophic Lateral Sclerosis (ALS)CompletedNCT01786174Phase 2Results posted
• Fingolimod in Schizophrenia PatientsCompletedNCT01779700Phase 2Results posted
• Fingolimod (FTY720) in Acute Demyelinating Optic Neuritis (ADON)TerminatedNCT01757691Phase 2Results posted
• A 3-year Multi-center Study to Describe Changes of OCT Parameters Under Treatment With Gilenya®CompletedNCT01705236Phase 4Results posted
• MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus CopaxoneTerminatedNCT01633112Phase 3Results posted
• Evaluate Efficacy and Safety of Fingolimod 0.5 mg Orally Once Daily Versus Placebo in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Patients.CompletedNCT01625182Phase 3Results posted
• Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.CompletedNCT01623596Phase 4Results posted
• STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)CompletedNCT01585298Phase 4Results posted
• A 12 -Month, Open-label, Multi-center Study to Explore the Health Outcomes of FTY720CompletedNCT01578330Phase 4Results posted
• Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg (EPOC)CompletedNCT01534182Phase 4Results posted
• Disease Control and Safety in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Switching From Natalizumab to FingolimodTerminatedNCT01499667Phase 3Results posted
• Efficacy of Fingolimod in de Novo Patients Versus Fingolimod in Patients Previously Treated With a First Line Disease Modifying TherapyCompletedNCT01498887Phase 4Results posted
• Safety and Tolerability of Fingolimod in Patients With Relapsing-remitting Multiple SclerosisCompletedNCT01497262Phase 3Results posted
• Fingolimod Versus Interferon Beta 1b in Cognitive SymptomsCompletedNCT01333501Phase 4Results posted
• Patients With Relapse Remitting Multiple Sclerosis (RRMS): Candidates for MS Therapy ChangeCompletedNCT01317004Phase 4Results posted
• A 6-month, Randomized, Open-label, Patient OutComes, Safety and Tolerability Study of Fingolimod (FTY720) 0.5 mg/Day vs. Comparator in Patients With Relapsing Forms of Multiple SclerosisCompletedNCT01216072Phase 4Results posted
• Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple SclerosisCompletedNCT01201356Phase 3Results posted
• Effect of Treatment With Fingolimod on the Immune Response Following Seasonal Flu Vaccination and Tetanus Booster Injection in Patients With Relapsing Multiple Sclerosis (MS)CompletedNCT01199861Phase 3Results posted
• This Was an Open-label, Single-arm Extension Study (CFTY720D2306E1) to a Double-blind, Randomized Multicenter, Placebo-controlled, Parallel-group Core Study (CFTY720D2306) in PPMS.TerminatedNCT00731692Phase 3Results posted
• An Extension Study of the Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing Multiple SclerosisCompletedNCT00670449Phase 2Results posted
• Long-term Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple SclerosisCompletedNCT00662649Phase 3Results posted
• Efficacy and Safety of FTY720 in Patients With Relapsing Multiple Sclerosis (MS)CompletedNCT00537082Phase 2Results posted
• Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple SclerosisCompletedNCT00355134Phase 3Results posted
• Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension PhaseCompletedNCT00340834Phase 3Results posted
• Efficacy and Safety of FTY720 in Patients With Relapsing Multiple SclerosisCompletedNCT00333138Phase 2Results posted
• Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple SclerosisCompletedNCT00289978Phase 3Results posted
• Oral Bio-equivalence StudyCompletedNCT05145621Phase 1
• Revascularization Pretreated With Fingolimod in Acute StrokeStatus unknownNCT04718064Not applicable
• Bioequivalence Study of Fingolimod From Sphingomod 0.5 mg Hard Gelatin Capsules (Hikma Pharma, Egypt) Versus Gilenya 0.5 mg Hard Capsules (Novartis Pharma AG, Basle, Switzerland).CompletedNCT04657744Phase 1
• Fingolimod in Endovascular Treatment of Ischemic StrokeStatus unknownNCT04629872Phase 2
• Fingolimod in COVID-19WithdrawnNCT04280588Phase 2
• Fingolimod in Treating Patients With Chemotherapy-Induced NeuropathyCompletedNCT03943498Early Phase 1
• Fingolimod in Preventing Paclitaxel-Associated Neuropathy in Patients With Breast CancerCompletedNCT03941743Phase 1
• Fingolimod Versus Dimethyl-fumarate in Multiple SclerosisTerminatedNCT03345940Phase 4
• Combinating Fingolimod With Alteplase Bridging With Mechanical Thrombectomy in Acute Ischemic StrokeWithdrawnNCT02956200Phase 2
• A Safety Study of Fingolimod With Radiation and Temozolomide in Newly Diagnosed High Grade GliomaCompletedNCT02490930Early Phase 1
• Study to Assess Immune Function and MRI Disease Activity in RRMS Patients When Switching From Natalizumab to GilenyaStatus unknownNCT02325440Phase 4
• Study to Assess Safety and Efficacy of Fingolimod in Children With Rett SyndromeCompletedNCT02061137Phase 1/2
• Efficacy and Safety of FTY720 for Acute StrokeCompletedNCT02002390Phase 2
• Safety and Efficacy of Fingolimod in MS Patients in ChinaWithdrawnNCT01941004Phase 3
• Study of FTY720 in Patients With UveitisWithdrawnNCT01791192Phase 2
• Long-term Effect of Fingolimod on Circulating Immunocompetent Mononuclear Cells in Patients With Multiple SclerosisTerminatedNCT01755871Phase 4
• ENGYNE Exploring Gilenya in Patients With Neutralizing Antibodies Against InterferonWithdrawnNCT01621269Phase 4
• Fingolimod -Response According to Coping - EvaluationCompletedNCT01420055Phase 4
• Biomarker Study After Initiation of Treatment With Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple SclerosisCompletedNCT01310166Phase 4
• Tolerability and Safety and Health Outcomes in Relapsing Multiple Sclerosis (MS) PatientsCompletedNCT01127750Phase 3
• A Study of the Effect of FTY720 on Pulmonary Function in Patients With Moderate AsthmaCompletedNCT00785083Phase 2
• Pharmacokinetics (PK) and Metabolism of FTY720 in Patients With Severe Renal Impairment and Healthy Matched Subjects.CompletedNCT00731523Phase 1
• Effects of FTY720 on Heart and Lung Functions in Healthy VolunteersCompletedNCT00416845Phase 1
• Efficacy and Safety of FTY720 in de Novo Adult Renal Transplant RecipientsCompletedNCT00239902Phase 2
• Efficacy and Safety of FTY720 in de Novo Adult Renal Transplant RecipientsCompletedNCT00239876Phase 3
• Efficacy and Safety of FTY720 Versus Mycophenolate Mofetil (MMF, Roche Brand) in de Novo Adult Renal Transplant RecipientsCompletedNCT00239863Phase 3
• Long Term Efficacy and Safety of FTY720 in de Novo Adult Renal Transplant RecipientsCompletedNCT00239811Phase 3
• Efficacy and Safety of FTY720 in de Novo Adult Renal Transplant RecipientsCompletedNCT00239798Phase 2
• Efficacy and Safety of FTY720 in de Novo Adult Renal Transplant RecipientsCompletedNCT00239785Phase 3
• Safety and Efficacy of FTY720 in Adult Patients Who Receive a Kidney TransplantCompletedNCT00099801Phase 3
• Safety and Efficacy of FTY720 in Adult Patients Who Receive a Kidney TransplantCompletedNCT00099749Phase 2/3
• Efficacy and Safety of FTY720 in Patients Who Receive a Kidney TransplantCompletedNCT00099736Phase 3
• Efficacy and Safety of FTY720 in Patients Who Receive a Kidney TransplantationCompletedNCT00098735Phase 3

← Fingolimod overview